Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. adviser seeks updates on pesticide impacts on non-target insects

Farmers Weekly reports that Robert Watson, chief scientific adviser at the United Kingdom's Department for Environment, Food and Rural Affairs, has asked for regular updates on new research into the possible effects of pesticides on non-target insects, not a full-scale review of neonicotinoids based on concerns regarding their impacts on bees, as previously reported by The Independent and others. DEFRA has considered all recent studies on neonicotinoids, including those suggesting imidacloprid makes honeybees more susceptible to a parasitic disease, and found they provide no new evidence. "The U.K. has a robust system for assessing risks from pesticides, and all the evidence shows neonicotinoids do not pose an unacceptable risk when products are used correctly," a DEFRA spokesman is quoted as saying by Farmers Weekly. "We will not hesitate to act if presented with any new evidence."

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG009219

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel